← 返回前沿论文

在早期 HER2 阳性乳腺癌患者中,将辅助帕妥珠单抗加入曲妥珠单抗和化疗的六年绝对无侵袭性疾病生存获益:APHINITY(BIG 4-11)试验的亚群治疗效果模式图(STEPP)分析

英文原题:Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.

查看英文原题

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.

PubMed 2022/03/18(内容时间) Eur J Cancer Q1 · IF 7.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

N-的 STEPP 图未识别出明显从加用 P 中获益的亚群,N+的 STEPP 图未识别出需要降阶梯治疗的亚群。TILs 百分比似乎比临床复合风险评分更能预测 P 的治疗效果。

研究思路结论见上方概要

APHINITY试验显示,在曲妥珠单抗和化疗的基础上加用辅助帕妥珠单抗(P),与加用安慰剂(Pla)相比,可显著改善HER2+早期乳腺癌患者的IDFS,无论是在总体人群还是在淋巴结阳性(N+)队列中。我们探讨了加用P是否可使某些N-亚组人群获益,以及是否应考虑对某些N+亚组人群进行降阶梯治疗。

亚群治疗效果模式图(STEPP)是一种探索性图形方法,用于绘制由感兴趣协变量定义的重叠患者亚群的治疗效果估计值。我们使用STEPP来估计6年IDFS百分比的Kaplan-Meier差异(P减去Pla:Δ ± 标准误[SE]),包括总体和按淋巴结状态,针对由以下因素定义的重叠亚群:(1)临床复合风险评分,(2)TIL(肿瘤浸润淋巴细胞)(TILs)百分比,以及(3)人表皮生长因子受体2(HER2)FISH拷贝数。由于多重性,Δ至少达到三个SE才值得关注。

6年IDFS百分比的平均绝对增益总体为2.8 ± 0.9;N+为4.5 ± 1.2,N-为0.1 ± 1.1。增益最大的是中等临床复合风险患者(总体5.3 ± 1.9;N+ 6.9 ± 2.3;N- 4.0 ± 3.0)、TILs百分比最高者(总体6.3 ± 1.7;N+ 7.4 ± 2.4;N- 3.2 ± 1.7)以及中等HER2拷贝数者(总体2.8 ± 1.9;N+ 7.4 ± 2.5;N- -1.3 ± 1.9),但缺乏明确证据表明存在亚群治疗效应差异的模式。

展开英文摘要原文

Subpopulation Treatment Effect Pattern Plot (STEPP) is an exploratory, graphical method that plots estimates of treatment effect for overlapping patient subpopulations defined by a covariate of interest. We used STEPP to estimate Kaplan-Meier differences in 6-year IDFS percentages (P minus Pla: Δ ± standard error [SE]), both overall and by nodal status, for overlapping subpopulations defined by (1) a clinical composite risk score, (2) tumour infiltrating lymphocytes (TILs) percentage, and (3) human epidermal growth factor receptor 2 (HER2) FISH copy number. Because of multiplicity, a Δ of at least three SE is required to warrant attention.

The average absolute gains in 6-year IDFS percentages were 2.8 ± 0.9 overall; 4.5 ± 1.2 for N+ and 0.1 ± 1.1 for N-. Largest gains were for patients with intermediate clinical composite risk (5.3 ± 1.9 overall; 6.9 ± 2.3 N+; 4.0 ± 3.0 N-), highest TILs percentage (6.3 ± 1.7 overall; 7.4 ± 2.4 N+; 3.2 ± 1.7 N-), and intermediate HER2 copy number (2.8 ± 1.9 overall; 7.4 ± 2.5 N+; -1.3 ± 1.9 N-), but clear evidence indicating a pattern of differential subpopulation treatment effects was lacking.

STEPP plots for N- did not identify subpopulations clearly benefiting from adding P, and those for N+ did not identify subpopulations warranting de-escalation. TILs percentage appeared to be more predictive of P treatment effect than clinical composite risk score. TRIAL REGISTRATION: clinicaltrials.gov Identifier NCT01358877.

论文信息

作者
Gelber RD、Wang XV、Cole BF、Cameron D、Cardoso F、Tjan-Heijnen V、Krop I、Loi S
第一作者单位
Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health, Frontier Science Foundation, Boston, MA, USA. Electronic address: gelber@jimmy.harvard.edu.United States
通讯作者单位
Institut Jules Bordet and L'Université Libre de Bruxelles (U.L.B), Brussels, Belgium. Electronic address: martine.piccart@bordet.be.Belgium
文献类型
临床试验
期刊
European journal of cancer (Oxford, England : 1990)2022 May
原文标识
PubMed 35313167 · DOI 10.1016/j.ejca.2022.01.031